Ionis Pharmaceuticals
Ionis Pharmaceuticals' revenue rose 33.8% to $944 million in fiscal 2025. Its operating margin was −40.5%, up from −67.4% a year earlier. Free cash flow was −$320 million. The diluted share count rose 7.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2017 to 2019, earnings per share grew 255.9% a year and net income 2,944.7% a year, as new shares raised the share count by 21% and diluted each share's earnings. Ionis Pharmaceuticals then lost money in fiscal 2020, 2021, 2022, 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 2,115 | 1,987 | 2,331 | 2,298 | 2,677 |
| Debt incl. finance leases | — | 1,194 | 1,308 | 1,253 | 1,812 |
| Net debt (negative means net cash) | — | −793 | −1,023 | −1,045 | −865 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 2.1x | 3.4x | 2.1x | 3.7x |
| Interest coverage | −3.2x | −50.5x | −27.9x | −28.0x | −22.1x |
| Current ratio | 9.8x | 7.1x | 5.9x | 8.5x | 3.8x |
| Quick ratio | 9.7x | 7.0x | 5.9x | 8.4x | 3.8x |
Cash flow
Projections
Project Ionis Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Ionis Pharmaceuticals says to expect
- Full year 2026: DAWNZERA product sales
On track to achieve full year 2026 product sales guidance of $110-120 million, representing a continuing driver of year-over-year revenue growth
- Full year 2026: TRYNGOLZA product sales
Full year 2026 product sales guidance lowered to approximately $50 million, reflecting a more gradual launch ramp than anticipated as Ionis establishes a new treatment paradigm for people with sHTG
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $1.1 million of Ionis Pharmaceuticals shares on the open market, and 17 insiders sold $117.5 million, $98.4 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | Michael R HaydenDirector | Bought | 5,000 | $51.60 | $258,000 | Form 4 |
| Jul 30, 2026 | Michael R HaydenDirector | Bought | 15,000 | $53.38 | $800,700 | Form 4 |
| Jul 7, 2026 | Bennett C FrankEVP, Chief Scientific Officer | Sold plan | 20,536 | $84.95 | $1.7 million | Form 4 |
| Jul 7, 2026 | Allene M. DiazDirector | Sold plan | 10,111 | $85.42 | $863,682 | Form 4 |
| Jul 7, 2026 | Holly B. KordasiewiczEVP, Chief Development Officer | Sold plan | 362 | $84.30 | $30,517 | Form 4 |
| Jul 1, 2026 | Joseph Klein IIIDirector | Sold plan | 11,518 | $79.04 | $910,423 | Form 4 |
| Jun 26, 2026 | Brett P MoniaChief Executive Officer, Director | Sold plan | 50,000 | $80.59 | $4.0 million | Form 4 |
| Jun 26, 2026 | Eugene SchneiderEVP, Chf Clinical Develop Ofcr | Sold plan | 26,000 | $81.05 | $2.1 million | Form 4 |
| Jun 26, 2026 | Joseph BaroldiEVP, Chief Business Officer | Sold plan | 5,635 | $80.16 | $451,702 | Form 4 |
| Jun 26, 2026 | Patrick R. O'NeilEVP CLO & General Counsel | Sold plan | 3,069 | $80.00 | $245,520 | Form 4 |
| Jun 25, 2026 | Brett P MoniaChief Executive Officer, Director | Sold plan | 21,072 | $78.49 | $1.7 million | Form 4 |
| Jun 25, 2026 | Eric SwayzeEVP Research | Sold plan | 10,602 | $79.18 | $839,466 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 2 of 9 | 3 of 9 |
| Rule of 40 | −8.0% | −87.9% | −0.1% |
| Altman Z'' | 2.22 | 1.80 | 1.12 |
| Accruals ratio | −2.1% | 1.6% | −3.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 3 of 9 | 2 of 9 | 3 of 9 |
Compare
Put Ionis Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals | FY25 | 33.8% | −40.5% | −33.9% | — | — | 3 | |
| Madrigal Pharmaceuticals | FY25 | 432.1% | −31.3% | −19.8% | — | — | 3 | Compare |
| Tilray Brands | FY26 | 11.5% | −6.9% | — | −3.4% | — | 3 | Compare |
| ANI Pharmaceuticals | FY25 | 43.8% | 12.6% | 19.4% | 15.9% | 0.1x | 6 | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 347 | 508 | 600 | 1,123 | 729 | 810 | 587 | 788 | 705 | 944 |
| Revenue growth | 22.2% | 46.5% | 18.1% | 87.2% | −35.0% | 11.1% | −27.5% | 34.1% | −10.5% | 33.8% |
| Gross profit | 347 | 508 | 598 | 1,118 | 717 | 800 | 573 | 778 | 694 | 928 |
| Research and development | 340 | 372 | 412 | 462 | 531 | 638 | — | 900 | 902 | 916 |
| Operating income | −20 | 31 | −61 | 366 | −172 | −30 | −410 | −354 | −475 | −382 |
| Net income | −60 | 0 | 274 | 278 | −444 | −29 | −270 | −366 | −454 | −381 |
| Diluted EPS (US$) | −0.50 | 0.15 | 2.07 | 1.90 | −3.18 | −0.20 | −1.90 | −2.56 | −3.04 | −2.38 |
| Diluted shares (millions) | 121 | 126 | 134 | 153 | 140 | 141 | 142 | 143 | 150 | 160 |
| Cash flow | ||||||||||
| Cash from operations | −112 | 174 | 603 | 346 | 36 | 31 | −274 | −308 | −501 | −269 |
| Capital expenditure | 7 | 35 | 14 | 31 | 35 | 12 | 16 | 24 | 45 | 51 |
| Free cash flow | −119 | 139 | 589 | 315 | 1 | 19 | −290 | −331 | −546 | −320 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 34 | 90 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 72 | 86 | 131 | 147 | 230 | 121 | 100 | 106 | 130 | 134 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 665 | 1,023 | 2,084 | 2,500 | 1,892 | 2,115 | 1,987 | 2,331 | 2,298 | 2,677 |
| Debt incl. finance leases | 502 | 535 | 582 | 788 | 840 | — | 1,194 | 1,308 | 1,253 | 1,812 |
| Total assets | 912 | 1,323 | 2,668 | 3,233 | 2,390 | 2,612 | 2,534 | 2,990 | 3,004 | 3,524 |
| Total liabilities | 813 | 958 | 1,481 | 1,549 | 1,646 | 1,840 | 1,961 | 2,603 | 2,415 | 3,035 |
| Shareholders' equity | 100 | 281 | 1,048 | 1,471 | 743 | 772 | 573 | 387 | 588 | 489 |
| Margins and ratios | ||||||||||
| Gross margin | 100.0% | 100.0% | 99.7% | 99.6% | 98.4% | 98.7% | 97.6% | 98.8% | 98.4% | 98.3% |
| Operating margin | −5.8% | 6.1% | −10.2% | 32.6% | −23.6% | −3.7% | −69.8% | −44.9% | −67.4% | −40.5% |
| Net margin | −17.4% | 0.1% | 45.6% | 24.8% | −60.9% | −3.5% | −45.9% | −46.5% | −64.4% | −40.4% |
| Free cash flow margin | −34.4% | 27.5% | 98.3% | 28.0% | 0.1% | 2.3% | −49.4% | −42.1% | −77.5% | −33.9% |
| Rule of 40 (growth + FCF margin) | −12.2% | 73.9% | 116.4% | 115.2% | −34.9% | 13.5% | −76.9% | −8.0% | −87.9% | −0.1% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −40.2% | 0.2% | 41.2% | 22.1% | −40.1% | −3.8% | −40.1% | −76.3% | −93.1% | −70.8% |
| Return on assets | −6.5% | 0.0% | 13.7% | 9.4% | −15.8% | −1.1% | −10.5% | −13.3% | −15.2% | −11.7% |
| Net debt to EBITDA | — | −12.4x | — | −4.5x | — | — | — | — | — | — |